Sagefield Capital’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Sagefield Capital’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-43,900	Closed	-$65.8K	–	108
2023 Q1	$65.8K	Buy	+43,900	New	+$59.1K	0.02%	94

Sagefield Capital's TCRR Position: Q2 2023 in Review

Sagefield Capital sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 43,900 shares — an estimated $65.8K sold.

Sagefield Capital first reported a position in TCRR in Q1 2023 and held it in 1 quarter. The position peaked at $65.8K in Q1 2023. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.

Sagefield Capital reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Sagefield Capital sold 43,900 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $65.8K.
Sagefield Capital first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Sagefield Capital's TCR2 Therapeutics Inc. Common Stock position peaked at $65.8K in Q1 2023.
0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.

Based on Sagefield Capital's 13F filing for Q2 2023, filed 14 Aug 2023.